Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Epithelial ovarian cancer is the most lethal gynecologic malignancy in the United States. Although patients initially respond to the current standard of care consisting of surgical debulking and combination chemotherapy consisting of platinum and taxane compounds, almost 90% of patients recur within a few years. In these patients the development of chemoresistant disease limits the efficacy of currently available chemotherapy agents and therefore contributes to the high mortality. To discover novel therapy options that can target recurrent disease, appropriate animal models that closely mimic the clinical profile of patients with recurrent ovarian cancer are required. The challenge in monitoring intra-peritoneal (i.p.) disease limits the use of i.p. models and thus most xenografts are established subcutaneously. We have developed a sensitive optical imaging platform that allows the detection and anatomical location of i.p. tumor mass. The platform includes the use of optical reporters that extend from the visible light range to near infrared, which in combination with 2-dimensional X-ray co-registration can provide anatomical location of molecular signals. Detection is significantly improved by the use of a rotation system that drives the animal to multiple angular positions for 360 degree imaging, allowing the identification of tumors that are not visible in single orientation. This platform provides a unique model to non-invasively monitor tumor growth and evaluate the efficacy of new therapies for the prevention or treatment of recurrent ovarian cancer.

[1]  J. Rao,et al.  Fluorescence imaging in vivo: recent advances. , 2007, Current opinion in biotechnology.

[2]  R. Chen,et al.  NV‐128, a novel isoflavone derivative, induces caspase‐independent cell death through the Akt/mammalian target of rapamycin pathway , 2009, Cancer.

[3]  O. Lapaire,et al.  The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging , 2014, Archives of Gynecology and Obstetrics.

[4]  G. Mor,et al.  Multimodality Animal Rotation Imaging System (MARS) for In Vivo Detection of Intraperitoneal Tumors , 2012, American journal of reproductive immunology.

[5]  M. de Jong,et al.  Of Mice and Humans: Are They the Same?—Implications in Cancer Translational Research , 2010, Journal of Nuclear Medicine.

[6]  G. Mor,et al.  Stem‐Like Ovarian Cancer Cells Can Serve as Tumor Vascular Progenitors , 2009, Stem cells.

[7]  Kathleen R. Cho,et al.  Ovarian cancer update: lessons from morphology, molecules, and mice. , 2009, Archives of pathology & laboratory medicine.

[8]  G. Mor,et al.  Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer , 2011, Journal of oncology.

[9]  G. Mor,et al.  Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment , 2013, Cancer Medicine.

[10]  D. Bergstrom,et al.  Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume , 2014, Clinical Cancer Research.

[11]  R. Chen,et al.  Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance , 2009, Cell cycle.

[12]  O. Cj,et al.  Frontiers in oncology. , 1990 .

[13]  Shengjie Li,et al.  Recent Advances , 2018, Journal of Optimization Theory and Applications.

[14]  M. Broggini,et al.  Revisiting ovarian cancer preclinical models: implications for a better management of the disease. , 2013, Cancer treatment reviews.

[15]  C. Annunziata,et al.  Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer , 2014, Front. Oncol..

[16]  C. Allen,et al.  Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer , 2008, Molecular Cancer Therapeutics.

[17]  D. Rimm,et al.  High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian Cancer , 2013, Reproductive Sciences.

[18]  R. Kutner,et al.  Production of Lentiviral Vectors in Protein‐free Media , 2011, Current protocols in cell biology.

[19]  Casey Weaver,et al.  Noninvasive bioluminescence imaging in small animals. , 2008, ILAR journal.

[20]  Kathleen R. Cho,et al.  Lessons From Morphology, Molecules, and Mice , 2009 .

[21]  C. Contag,et al.  Advances in in vivo bioluminescence imaging of gene expression. , 2002, Annual review of biomedical engineering.

[22]  S. Langdon Animal modeling of cancer pathology and studying tumor response to therapy. , 2012, Current drug targets.

[23]  S. Nuti,et al.  Constitutive Proteasomal Degradation of TWIST-1 in Epithelial Ovarian Cancer Stem Cells Impacts Differentiation and Metastatic Potential , 2012, Oncogene.

[24]  G. Mor,et al.  TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence , 2013, Cell cycle.

[25]  J. Hickson In vivo optical imaging: preclinical applications and considerations. , 2009, Urologic oncology.

[26]  J. Richards,et al.  Minireview: animal models and mechanisms of ovarian cancer development. , 2012, Endocrinology.